Ascelia Pharma wins the award for Best Life Science company in Malmö

2020-02-11
Download
Ascelia Pharma AB (publ) (ticker: ACE) was yesterday evening awarded the price for best Life Science company in Malmö at the city’s prestigious annual corporate awards (Malmö Näringslivsgala). The price award follows Ascelia Pharma’s work on developing novel drug candidates that fill a distinct unmet medical need.

“We are very pleased and honored by the award that emphasises our diligent work to develop novel drugs that improve the life expectancy and quality of life for people living with cancer. As communicated earlier, we have opened sites for patient enrolment in our registration-enabling Phase III study for our lead drug candidate Mangoral and expect sales launch in 2022 in the US. To ensure continued successful development, we are expanding our company in Malmö”, said Magnus Corfitzen, CEO of Ascelia Pharma.

 

For more information, please contact:
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.

2021-05-12

Quarterly Report Q1 2021: US office opened in preparation of launch

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q1 2021 (January – March 2021), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations
2021-05-05

Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2021

Today, on 5 May 2021, the annual general meeting was held in Ascelia Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting was held only by advance voting (postal vote) in accordance with temporary legislation. A summary of the adopted resolutions follows below. All resolutions were adopted with the required majority of votes.
2021-04-30

Number of shares and votes in Ascelia Pharma AB